Clene Inc. Common Stock
CLNNClene Inc. (CLNN) is a biotechnology company focused on developing therapies for neurodegenerative diseases and other serious medical conditions. The company specializes in harnessing nanocatalysis technology to create treatments aimed at restoring cellular health and function. Their research primarily targets conditions such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
Company News
Clene Inc. announced key 2026 milestones for its investigational ALS drug CNM-Au8, including an FDA Type C meeting by Q1 2026, NDA submission via accelerated pathway in Q2 2026, and potential PDUFA date in H2 2026. The company secured $28 million in funding with runway into Q4 2026, and plans to initiate a Phase 3 confirmatory trial later in 2026...
Clene Inc. will host an investor call and webcast on December 3, 2025, to provide an update on its CNM-Au8 program for treating amyotrophic lateral sclerosis (ALS). The company is a late clinical-stage biopharmaceutical firm focused on neurodegenerative disease treatments.
Clene, a clinical-stage biopharmaceutical company, reported a net loss of $(0.78) per share in Q2 2025, with minimal revenue of $27,000. The company continues advancing its CNM-Au8 therapy for neurodegenerative diseases while managing tight cash resources.
Clene Inc., a clinical-stage biopharmaceutical company, announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings on September 9, 2024.
